We have a portfolio of drugs in-licensed for clinical development using the re-purposing 505(b)(2) regulatory pathway.
Some of the indications we’re working on are orphan diseases and unmet medical needs in the mental disorders .
Astimum is in the process of raising funds to take development of its assets further. Please get in touch with us at Investors@Astimum.com.
We are grateful to our Series A lead investor BioIdeations for the strategic support provided so far.